Literature DB >> 2044655

T and B cell collaboration: induction of motility in small, resting B cells by interleukin 4.

B Clinchy1, C Elenström, E Severinson, G Möller.   

Abstract

In this report we investigate if IL 4 can work as a chemoattractant factor by inducing locomotion in B cells. We found that murine recombinant IL 4 (rIL 4) induced motile morphology and migration through polycarbonate micropore filters of murine, splenic B cells at an optimal concentration of 3 ng/ml. Kinetic studies revealed optimal migration at 8-16 h, although a significant response could be detected already after 1 h. Flow cytometric studies confirmed that the migrated cells were indeed B cells. We also compared the activity of small, dense B cells and large, low-density B cells, based on Percoll gradient separation. We found no difference in IL 4-induced motility among the two groups. Furthermore, we looked at B cells activated in vitro by preculture in lipopolysaccharide (LPS) or IL 4. Our data indicate that both LPS and IL 4 can increase the general capacity for motility in B cells after preculture for 24 h. T and B cell collaboration requires close cell-cell contacts in order for T cell help to be administered to the B cell. One way of enhancing such cell contacts could be through directional cell migration induced by helper factors (chemotaxis). We suggest that IL 4 can play a role as a chemoattractant factor that enhances cell contacts between T helper cells and B cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2044655     DOI: 10.1002/eji.1830210618

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  9 in total

1.  CD44-stimulated dendrite formation ('spreading') in activated B cells.

Authors:  L Santos-Argumedo; P W Kincade; S Partida-Sánchez; R M Parkhouse
Journal:  Immunology       Date:  1997-01       Impact factor: 7.397

2.  Locomotor properties of human germinal centre B cells: activation by anti-CD40 and IL-4 allows chemoattraction by anti-immunoglobulin.

Authors:  M Komai-Koma; P C Wilkinson
Journal:  Immunology       Date:  1997-01       Impact factor: 7.397

3.  Interleukin (IL)-4 induces production of cytokine-induced neutrophil chemoattractants (CINCs) and intercellular adhesion molecule (ICAM)-1 in lungs of asthmatic rats.

Authors:  Ya-Li Guo; Hong Huang; Da-Xiong Zeng; Jian-Ping Zhao; Hui-Juan Fang; Jean-Pierre Lavoie
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-08-01

4.  Kaposi's sarcoma-associated herpesvirus inhibits interleukin-4-mediated STAT6 phosphorylation to regulate apoptosis and maintain latency.

Authors:  Qiliang Cai; Subhash C Verma; Ji-Young Choi; Michelle Ma; Erle S Robertson
Journal:  J Virol       Date:  2010-08-18       Impact factor: 5.103

5.  Inhibition of LFA-1-dependent human B-cell aggregation induced by CD40 antibodies and interleukin-4 leads to decreased IgE synthesis.

Authors:  P Björck; S Paulie
Journal:  Immunology       Date:  1993-02       Impact factor: 7.397

6.  Association study between clinicopathological variables and periodontal breakdown in gingival pyogenic granuloma.

Authors:  Leonor V González-Pérez; Diana M Isaza-Guzmán; Sergio I Tobón-Arroyave
Journal:  Clin Oral Investig       Date:  2014-02-05       Impact factor: 3.573

7.  Interleukin-10 inhibits motility in murine and human B lymphocytes.

Authors:  B Clinchy; P Björck; S Paulie; G Möller
Journal:  Immunology       Date:  1994-07       Impact factor: 7.397

8.  Efficient antigen presentation of soluble, but not particulate, antigen in the absence of Wiskott-Aldrich syndrome protein.

Authors:  Lisa Westerberg; Robert P A Wallin; Gediminas Greicius; Hans-Gustaf Ljunggren; Eva Severinson
Journal:  Immunology       Date:  2003-07       Impact factor: 7.397

9.  Interleukin (IL)-4 induces leukocyte infiltration in vivo by an indirect mechanism.

Authors:  Claude Ratthé; Jamila Ennaciri; David M Garcês Gonçalves; Sonia Chiasson; Denis Girard
Journal:  Mediators Inflamm       Date:  2009-09-10       Impact factor: 4.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.